AstraZeneca 3Q Farxiga Sales Fall 25% at Constant Currency
Farxiga sales were $1.605 billion in the third quarter, down 25% at constant currency.
Related stories
Panasonic Raises Operating Profit Forecast After Q2 Increase
Panasonic reported higher operating profit in the second quarter and raised its forecasts.
M impact | EARNINGS | Oct 30, 2026, 07:58 AM UTC
Erste Raises 2026 Loan and Net Interest Income Outlook
Erste Group raised its 2026 loan volume target to above €290 billion and forecast net interest income growth of more than 6% excluding Poland, up from about 5% previously.
M impact | EARNINGS | Oct 30, 2026, 07:52 AM UTC
AstraZeneca 3Q Results Beat Expectations, JPMorgan Says
J.P. Morgan analysts said AstraZeneca beat expectations on revenue and the bottom line and reiterated its 2026 and 2030 guidance. The analysts expect a positive share reaction.
H impact | EARNINGS | Oct 30, 2026, 07:46 AM UTC
AstraZeneca Reports Third-Quarter Revenue and Profit Growth
AstraZeneca said third-quarter revenue and profit increased, with strong cancer-drug sales offsetting the effect of patent expirations.
M impact | EQUITY | Oct 30, 2026, 07:40 AM UTC
Iron Ore Slips on Weak Fundamentals
Iron ore futures fell below CNY 680 per ton, sliding toward four-year lows as rising port inventories, subdued steel mill profitability and sluggish demand continued to pressure pr
L impact | EARNINGS | Oct 30, 2026, 07:20 AM UTC
Airtel Africa H1 Revenue Rises Across Regions and Segments
M impact | EARNINGS | Oct 30, 2026, 07:17 AM UTC